Emax

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

Retrieved on: 
Tuesday, March 26, 2024
Research, Toxicity, Central nervous system, PIN, Administration, Immunotherapy, Emax, Science, Patient, AstraZeneca, Food and Drug Administration, Biomarker, G&A, Plaque, Chemistry, Therapy, Neurogranin, Safety, ABOS, Research and development, Plasma protein binding, Food, Pharmaceutical industry

We delivered the first Phase 1 results from an oligomer-targeted antibody for the treatment of early Alzheimer’s disease, which exceeded expectations.

Key Points: 
  • We delivered the first Phase 1 results from an oligomer-targeted antibody for the treatment of early Alzheimer’s disease, which exceeded expectations.
  • We also expect to initiate a subcutaneous bioavailability study in mid-2024, to extend the product profile and offer administration optionality for patients.
  • Dr. Doherty brings decades of neuroscience-focused research and clinical development expertise to Acumen, from discovery through drug approval.
  • Net loss for the year ended December 31, 2023 was $52.4 million, compared to a net loss of $42.9 million for the year ended December 31, 2022.

Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease

Retrieved on: 
Friday, October 27, 2023
Trial of the century, AD, Incidence, Plaque, Fluid mechanics, CSF, Complex, Data, CNS, PET, Pharmacokinetics, ABOS, Clinical trial, PK, Congress, Serum, Brain, Safety, Fluid, Patient, Amyloid plaques, Central nervous system, Medical imaging, Pharmaceutical industry, Vaccine, Emax, Acumen

CHARLOTTESVILLE, Va. and INDIANAPOLIS, Ind., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today presented further analyses of the Phase 1 INTERCEPT-AD trial evaluating ACU193, the first clinical-stage AβO-targeting antibody, at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston and online. The additional analyses reveal robust target engagement data modeling informing dose selection for Acumen’s upcoming Phase 2/3 trial, as well as further details and characteristics around the observed plaque reduction and relatively low overall levels of ARIA-E during a late breaking symposium. Acumen additionally presented new target engagement and pharmacokinetic (PK) analyses from clinical trial recruitment in four posters at the conference.

Key Points: 
  • Acumen additionally presented new target engagement and pharmacokinetic (PK) analyses from clinical trial recruitment in four posters at the conference.
  • Acumen plans to progress to a Phase 2/3 clinical study, with the Phase 2 portion planned to begin in the first half of 2024.
  • A Phase 2/3 study is planned to assess primarily the clinical efficacy of ACU193 and also to more fully understand its effect on plaques.
  • The full results of the INTERCEPT-AD study will be presented at a future medical congress and submitted for publication in a peer-reviewed clinical journal.

Upstream Bio Announces Positive Phase 1b Interim Data in Asthma and Company Progress Toward Phase 2

Retrieved on: 
Tuesday, October 24, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, PD, Bio, Nitric acid, Emax, MD, MAD, Inflammation, Volunteering, Caregiver, Thymic stromal lymphopoietin, Sinusitis, Partnership, Asthma, Research and development, Congress, Safety, Polyp (medicine), Patient, SC, Pharmaceutical industry, Research

Upstream Bio , a clinical-stage biotech company advancing new therapies to treat inflammation, today announced positive interim results in its Phase 1b clinical study of UPB-101, a thymic stromal lymphopoietin receptor (TSLPR) inhibitor.

Key Points: 
  • Upstream Bio , a clinical-stage biotech company advancing new therapies to treat inflammation, today announced positive interim results in its Phase 1b clinical study of UPB-101, a thymic stromal lymphopoietin receptor (TSLPR) inhibitor.
  • The Phase 1b study is a randomized, double-blinded, placebo-controlled multiple ascending dose (MAD) study with subcutaneous (SC) administration​ conducted in asthma patients.
  • The interim data results demonstrated favorable safety, tolerability, immunogenicity, pharmacokinetic (PK) and pharmacodynamic (PD) markers that strongly support moving to Phase 2.
  • “The Upstream team is taking swift steps to move into our global Phase 2 studies in severe asthma and CRSwNP by Q1 2024.

Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology

Retrieved on: 
Tuesday, October 3, 2023
Blood pressure, Exercise, Cleveland Clinic, University, Pediatrics, ARS, Symantec Endpoint Protection, Clinical trial, NDA, VAS, American Academy, American Academy of Allergy, Asthma, and Immunology, Trial of the century, Committee, Asthma, Rhinitis, Literature, The Journal of Allergy and Clinical Immunology, Journal, Patient, Translational research, Anaphylaxis, Adrenaline, SAN, Irritation, Epinephrine autoinjector, HR, AAAAI, Cleveland, Heart rate, Caregiver, FDA, Safety, Complete Response Letter, Emax, Palladium, Pharmaceutical industry, Vaccine, SBP, PD, Allergy, Immunology, Medicine

JACI is the official scientific publication of the American Academy of Allergy, Asthma and Immunology and the most cited journal in the field of allergy and clinical immunology.

Key Points: 
  • JACI is the official scientific publication of the American Academy of Allergy, Asthma and Immunology and the most cited journal in the field of allergy and clinical immunology.
  • The clinical study evaluated single and repeat doses of neffy compared to single and repeat doses of approved injection products in healthy subjects.
  • For repeat doses of neffy, mean maximum changes in PD responses for both blood pressure and heart rate were statistically greater than repeat doses of EpiPen.
  • In addition, the PK profile for a second dose of neffy was approximately dose-proportional, unlike EpiPen, where the second dose delivered less incremental epinephrine exposure than the first dose.

Acumen Pharmaceuticals Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023

Retrieved on: 
Sunday, July 16, 2023
Columbia University, Cognition, PK, McKnight Brain Institute, University, Alzheimer's disease, Serum, SAD, Brain, Biomarker, Siemens, PIN, AAIC, Magnetic resonance imaging, Feature, Patient, ASL, Webcast, MAD, CSF, Emax, Vaccine, Acumen

Denominator of 14 participants in 10 mg/kg, 25 mg/kg and 60 mg/kg inclusive of single-ascending dose and multiple-ascending dose cohorts.

Key Points: 
  • Denominator of 14 participants in 10 mg/kg, 25 mg/kg and 60 mg/kg inclusive of single-ascending dose and multiple-ascending dose cohorts.
  • In both the SAD and MAD cohorts of the study, clear evidence of a dose relationship was observed for ACU193 exposure.
  • Levels of ACU193 detected in CSF in all cohorts were in excess of endogenous levels of AβOs reported in CSF.
  • Acumen will host a webcast presentation and conference call for analysts and investors on Monday, July 17, 2023, at 8:00 a.m.

Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate

Retrieved on: 
Monday, November 14, 2022
Psilocybin, Psilocin, MSET, CSE, Mouse, EC50, BT, Pathology, Society for Neuroscience, FSE, Pharmacokinetics, ED50, Otsuka Pharmaceutical, LMA, Prodrug, Safety, Society, RATS, Depression, CSO, Development, Drug discovery, Behavior, SC, SFN, Patient, Pharmaceutical industry, Emax, Mindset, Neuroscience

Joseph Araujo, Chief Scientific Officer, Director of Mindset Pharma, presented the findings at Neuroscience 2022 hosted by the Society of Neuroscience (SfN) in a poster titled The Preclinical Safety, Behavioural and Pharmacokinetics Properties of MSP-1014, a Novel Prodrug of Psilocin .

Key Points: 
  • Joseph Araujo, Chief Scientific Officer, Director of Mindset Pharma, presented the findings at Neuroscience 2022 hosted by the Society of Neuroscience (SfN) in a poster titled The Preclinical Safety, Behavioural and Pharmacokinetics Properties of MSP-1014, a Novel Prodrug of Psilocin .
  • Psilocybin is a dihydrogen phosphonate prodrug of psilocin, which is thought to mediate antidepressant effects primarily by activation of 5-HT2A receptor subtype.
  • MSP-1014 was also evaluated in a drug discrimination assay in which rats were trained to discriminate a psilocybin cue from saline.
  • Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.

Landmark Group Selects E2open to Enhance Supply Chain Resiliency

Retrieved on: 
Thursday, June 2, 2022
Software, Networks, Other Retail, Data Management, Technology, Supply Chain Management, Mobile, Wireless, Retail, Fitness First, Landmark Group, Food, LLC, Transport, Artificial intelligence, Group, VIVA, Workforce, Entrepreneurship, Machine learning, Emax, Great Places, Technology, NYSE, Compliance, E2open, MENA, Efficiency, Family, Home Box Office, Inc., Retail, Warehouse

E2open Parent Holdings, Inc. (NYSE: ETWO), a leading network-based provider of a cloud-based, mission-critical, end-to-end supply chain management platform, announces that Landmark Group , a multinational retail and hospitality conglomerate, has selected E2open to improve competitive advantage for its retail division.

Key Points: 
  • E2open Parent Holdings, Inc. (NYSE: ETWO), a leading network-based provider of a cloud-based, mission-critical, end-to-end supply chain management platform, announces that Landmark Group , a multinational retail and hospitality conglomerate, has selected E2open to improve competitive advantage for its retail division.
  • Landmark Group will deploy E2open to revolutionize its supply chain operations, covering collaboration on procurement to optimizing transportation planning execution and managing trade compliance.
  • This is exactly the task Landmark Group is entrusting to E2open - to modernize its supply chain operations with visibility and collaboration to deliver value for a diverse range of customers.
  • We are constantly striving to deliver exceptional value and retail experiences and therefore developing an agile supply chain is part of the Groups supply chain vision, said Ashish Sood, Landmark Groups chief supply chain officer.

OPPO Reno6 series, OPPO Enco Air and OPPO Enco Buds wireless headphones on sale now in The Middle East

Retrieved on: 
Monday, September 20, 2021
Cloud, AED, Elan, ColorOS, OPPO, MEA, Music, Series, Jumbo, Memory, Smartphone, Software, Jackie Akello, GCC, TikTok, MENA, International, Emax, Technology, Research, GB, Mobile phone

DUBAI, UAE, Sept. 20, 2021 /PRNewswire/ -- The newly-launched OPPO Reno6 Series, OPPO Enco Air and Enco Buds wireless headphones are now available to purchase in the Middle East.

Key Points: 
  • DUBAI, UAE, Sept. 20, 2021 /PRNewswire/ -- The newly-launched OPPO Reno6 Series, OPPO Enco Air and Enco Buds wireless headphones are now available to purchase in the Middle East.
  • Alongside the smartphone launch, OPPO has also introduced two True Wireless Earphones, OPPO Enco Air and OPPO Enco Buds as well as a Portrait Lighting Protective Case for the Reno6 5G , which provides intelligent selfie lighting without the need for additional power supply or charging.
  • OPPO brings the aesthetics of technology of global consumers through the ColorOS system Experience, and Internet service like OPPO Cloud and OPPO+.
  • This has included the launch of its flagship OPPO Find X Series and the introduction of the OPPO Reno Series.

OPPO Reno6 series, OPPO Enco Air and OPPO Enco Buds wireless headphones on sale now in The Middle East

Retrieved on: 
Monday, September 20, 2021
Cloud, AED, Elan, ColorOS, OPPO, MEA, Music, Series, Jumbo, Memory, Smartphone, Software, Multimedia, Jackie Akello, GCC, TikTok, MENA, International, Emax, Technology, View, Research, GB, Mobile phone

DUBAI, UAE, Sept. 20, 2021 /PRNewswire/ -- The newly-launched OPPO Reno6 Series, OPPO Enco Air and Enco Buds wireless headphones are now available to purchase in the Middle East.

Key Points: 
  • DUBAI, UAE, Sept. 20, 2021 /PRNewswire/ -- The newly-launched OPPO Reno6 Series, OPPO Enco Air and Enco Buds wireless headphones are now available to purchase in the Middle East.
  • Alongside the smartphone launch, OPPO has also introduced two True Wireless Earphones, OPPO Enco Air and OPPO Enco Buds as well as a Portrait Lighting Protective Case for the Reno6 5G , which provides intelligent selfie lighting without the need for additional power supply or charging.
  • OPPO brings the aesthetics of technology of global consumers through the ColorOS system Experience, and Internet service like OPPO Cloud and OPPO+.
  • Within the last year, OPPO has started to adjust its product line in the Middle East region specifically.

Longeveron Announces Topline Results of Phase 2b Study of Lomecel-B for Aging Frailty

Retrieved on: 
Friday, August 13, 2021
Forward-looking statement, Intussusception (medical disorder), Clinical trial, Muscle, ADL, Calendar, Observation, HLHS, CGMP, NIA, Emax, Safety, Pros, National Institute on Aging, Company, SBIR, Risk, SEC, Miami, Telephone, FDA, Fear, Cognition, Particle-size distribution, Depression, Weight loss, Inflammation, Infection, Population, Adult, Walking, CEO, Microsoft, Goal, Patent, Intention, Cell, Small Business Innovation Research, Fatigue, Conference, Metabolic syndrome, Bone marrow, National academy, Malnutrition, Physician, International Conference on the Holocaust and Genocide, Hospital, NASDAQ, Terminology, Serum, Hypoplastic left heart syndrome, Disorder, National Academy of Medicine, Linearity, National Institute, Education, Program, Immune system, GLOBE, CHSA, Medical imaging, Pharmaceutical industry, Fertilizer

MIAMI, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced results from the Company’s Phase 2b trial titled: A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Lomecel-B Infusion in Patients With Aging Frailty (the “Phase 2b trial”). Lomecel-B is a proprietary allogeneic product comprised of medicinal signaling cells (MSCs) from the bone marrow of adult donors and culture-expanded in Longeveron’s current good manufacturing practice (cGMP) cell processing facility. The Phase 2b trial, which was partially funded by a Small Business Innovation Research (SBIR) grant from the National Institute on Aging (NIA), evaluated the safety and efficacy of a single peripheral intravenous infusion of four different doses of Lomecel-B cell therapy (25 million (n=37), 50 million (n=31), 100 million (n=34) and 200 million (n=16) cells; sample size reflects any subject that was randomized and received an infusion) compared to placebo (n=30), on signs and symptoms of Aging Frailty, including mobility and exercise tolerance.

Key Points: 
  • About the US Phase 2b Aging Frailty Trial:
    The primary objective of this multi-center study is to assess the effect of Lomecel-B on exercise tolerance and endurance via the six-minute walk test (6MWT).
  • Aging Frailty is a life-threatening geriatric condition affecting approximately 15% of Americans over the age of 65, or 8.1 million individuals.
  • The necessity for identifying patients with Aging Frailty is well-acknowledged in the geriatric community, and the treatment of Aging Frailty and promotion of healthful aging are recognized priorities of the National Academy of Medicine and NIA/NIH.
  • Despite the pressing need for interventions, there are no FDA-approved therapies that can slow down, reverse, or prevent Aging Frailty.